This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"One Chinese sector being relatively ignored by Wall Street is the biotech industry," notes Keith Fitz-Gerald. In The New China Trader, he looks to a biotech speculation -- Sinovac (AMEX: SVA).

"The government knows that the wheels could fall off the bike rather quickly if average Chinese citizens begin to see a dramatic reversal in their health and happiness.

Continue reading Sinovac (SVA): Chinese biotech bet

Sinovac (SVA): Chinese biotech bet originally appeared on BloggingStocks on Mon, 11 May 2009 13:50:00 EST. Please see our terms for use of feeds.

Those surprised by the market's strength in recent weeks should be even more impressed with the rebound in China, where both their market and economy have proven among the most resilient in the world.

Global specialist Nicholas Vardy adds, "While the US markets are rising, Asian stocks are on fire." ETF expert Paul Tracy adds, "China funds have screamed to the top of the performance charts."

In large part, this strength is due to the country's stimulus program. Tracy points out, "To combat the sagging global economy, Chinese Premier Wen Jiabao orchestrated a massive 4 trillion yuan ($586 billion) stimulus package.

Continue reading Investing in China: 12 experts pick their best bets

Investing in China: 12 experts pick their best bets originally appeared on BloggingStocks on Fri, 08 May 2009 10:30:00 EST. Please see our terms for use of feeds.